The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks
Source: Streetwise Reports (12/16/2025)

Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly.

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff
Source: Streetwise Reports (12/15/2025)

Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains.

AI-Powered Healthcare Co. Gains Traction as US Expansion Accelerates
Source: John Newell (12/08/2025)

John Newell of John Newell & Associates shares why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.

Clean Tech Co.'s 'Forever Chemicals' Solution Featured in Industry Magazine
Source: Streetwise Reports (12/08/2025)

BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term.

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe (12/04/2025)

Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report.